
Syneos Health SYNH
Quarterly report 2023-Q1
added 05-10-2023
Syneos Health Accounts Receivables 2011-2026 | SYNH
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Syneos Health
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 729 M | - | 211 M | 158 M | 130 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 729 M | 130 M | 307 M |
Quarterly Accounts Receivables Syneos Health
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | 782 M | 769 M | 776 M | 724 M | 729 M | 729 M | 729 M | 729 M | 643 M | 643 M | 643 M | 188 M | 211 M | 179 M | 190 M | 211 M | 158 M | 158 M | 158 M | 158 M | 130 M | 130 M | 130 M | 130 M | 130 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 782 M | 130 M | 406 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M | ||
|
BioNano Genomics
BNGO
|
4.75 M | $ 1.15 | 2.87 % | $ 1.46 M | ||
|
Burning Rock Biotech Limited
BNR
|
88.2 M | $ 26.19 | -5.21 % | $ 281 M | ||
|
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | ||
|
DarioHealth Corp.
DRIO
|
3.16 M | $ 11.26 | - | $ 319 M | ||
|
Danaher Corporation
DHR
|
3.91 B | $ 209.01 | -0.09 % | $ 149 B | ||
|
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | ||
|
Fulgent Genetics
FLGT
|
69 M | $ 23.5 | 1.75 % | $ 711 M | ||
|
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | ||
|
Co-Diagnostics
CODX
|
304 K | - | - | $ 79.8 M | ||
|
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M | ||
|
Quest Diagnostics Incorporated
DGX
|
1.3 B | $ 208.53 | -0.48 % | $ 23.1 B | ||
|
Castle Biosciences
CSTL
|
51.2 M | $ 30.18 | 0.8 % | $ 838 M | ||
|
CareDx, Inc
CDNA
|
51.1 M | $ 17.83 | -7.38 % | $ 959 M | ||
|
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | ||
|
DexCom
DXCM
|
1.22 B | $ 72.7 | -0.53 % | $ 28.4 B | ||
|
Laboratory Corporation of America Holdings
LH
|
2.1 B | $ 285.15 | -0.7 % | $ 23.7 B | ||
|
Interpace Biosciences
IDXG
|
8.54 M | $ 1.74 | -5.95 % | $ 7.63 M | ||
|
Exact Sciences Corporation
EXAS
|
299 M | $ 103.32 | -0.13 % | $ 19.5 B | ||
|
Myriad Genetics
MYGN
|
115 M | $ 4.54 | 2.37 % | $ 420 M | ||
|
Natera
NTRA
|
244 M | $ 212.24 | 1.29 % | $ 20.9 B | ||
|
Guardant Health
GH
|
138 M | $ 96.53 | 1.18 % | $ 12.1 B | ||
|
Pacific Biosciences of California
PACB
|
36.6 M | $ 1.66 | -0.3 % | $ 421 M | ||
|
QIAGEN N.V.
QGEN
|
381 M | - | - | $ 10.6 B | ||
|
Charles River Laboratories International
CRL
|
709 M | $ 170.51 | 2.68 % | $ 8.45 B | ||
|
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
1.34 B | $ 101.36 | -2.62 % | $ 8.36 B | ||
|
ENDRA Life Sciences
NDRA
|
6.85 K | $ 3.76 | -2.72 % | $ 2.02 M | ||
|
IDEXX Laboratories
IDXX
|
552 M | $ 657.74 | 1.31 % | $ 52.9 B | ||
|
Illumina
ILMN
|
735 M | $ 123.08 | 0.14 % | $ 19.6 B | ||
|
IQVIA Holdings
IQV
|
3.4 B | $ 160.89 | -2.37 % | $ 27.7 B | ||
|
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
778 M | $ 1 370.32 | -0.56 % | $ 28.2 B | ||
|
Biodesix
BDSX
|
8.6 M | $ 13.16 | 1.08 % | $ 1.71 B | ||
|
Lantheus Holdings
LNTH
|
321 M | $ 74.58 | 1.31 % | $ 5.16 B |